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The mortality of patients suffering peripheral arterial
disease (PAD) depends on the severity of the disease.
Patients suffering critical limb ischemia (CLI) have an
annual mortality of 10±15%, whereas it is 4±6% for
those `` only'' suffering claudication.1±4 Compared to
the people of similar age, without symptoms of ath-
erosclerosis, the mortality of PAD patients is increased
by a factor 2±4, i.e. similar to that of patients with
coronary heart disease (CAD). This increased risk of
death is of course accounted for by the presence of
concomitant CAD. Hertzer et al.4 performed coronary
angiograms on a series of patients undergoing peri-
pheral arterial reconstruction because of CLI and
found 90% to have significant CAD. Interestingly,
amputation, which many patients with PAD fear
most seems a uncommon event (1±3% in 5 years),
compared to the risk of death (30%).1
Thus, patients with PAD have two separate
problems that require consideration when evaluated
by the physician:
(1) The symptoms from the lower limbs ± most
important with respect to the patients complaints
(2) The general risk of atherosclerosis even if the
patient is unaware of any symptoms of CAD or
cerebrovascular disease ± most important with
respect to the patients survival.
Looking at the former, we as vascular surgeons have
a long tradition for treating lower limb ischemia. ThisPlease address all correspondence to: Gentofte University
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last decades, evident by the increasing proportion of
patients being treated by endovascular methods. Also,
non-surgical therapies are constantly being evaluated.
Even though surgery is the most challenging aspect
for the surgeon, the primary recommendation for
the claudicant remains walking exercise as evident
in the TASC report and other recent publications.5±7
Pharmacological treatment to improve walking dis-
tance has so far not gained widespread acceptance,
mainly due to the inadequacy of the available
drugs, although recent developments may be more
positive.8
Turning to the overall risk of atherosclerosis in PAD
patients, it is evident that our patients die from CAD
or stroke. However, is there any evidence that treat-
ment of risk factors for CAD will affect the outcome
of the PAD patient?
The main mechanism for development of athero-
sclerotic plaques is the accumulation of cholesterol
in the vessel wall. Thus, much therapy been directed
towards preventing or slowing this process, most
notably by cholesterol lowering agents, e.g. statins.
The positive effect of these drugs within CAD is
indisputable today, thus, in most western countries
there are recommendations stating the need for statin
treatment in CAD. The average risk reduction looking
at hard end-points (death and myocardial infarction)
is around 25±30% in all studies.9±13 Although there is
every reason to believe that statins are beneficial for
patients suffering from peripheral arterial disease, no
published studies exist for this group as most patients
in these studies suffered from CAD. Recently, the
Heart Protection study was presented at the American
Heart Association, November 2001, indicating thatll rights reserved.
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from statin treatment, as evaluated by a composite
end-point including death, myocardial infarction,
stroke and revascularisation.14 Similarly, very few
would question the beneficial effect of aspirin in
PAD patients, although the evidence for this drug
lies in its use in patients suffering from CAD and
stroke.15 Recent data from the HOPE study, including
a substudy on patients with reduced ankle-brachial
indices, indicate that ACE-inhibitors also reduce
cardiovascular morbidity in PAD patients.16,17 Most
national and international recommendations, in-
cluding the latest North American, NCEP III,18
accordingly recommend that the risk factors in
patients with PAD should be treated in the same
way as those with CAD.
What is the level of risk factor reduction in
PAD patients?
The level of risk factor reduction in patients with PAD
has been found to be limited and much less than that
offered to patients with CAD. In a Danish study only
5% of patients operated for CLI were on statin treat-
ment and only 40% were taking aspirin, despite the
fact that 30% of these patients had symptomatic
CAD.3 Similarly, in American studies of primary care
and in vascular surgical departments, PAD patients
were found to be undertreated and treated much less
than CAD patients with respect to secondary medical
prevention.19,20
Why are patients suffering PAD offered less risk
factor reduction?
There are probably a number of reasons. Firstly, the
scientific evidence proving the benefit in patients with
PAD has been slow in coming. Thus, vascular sur-
geons, traditionally being involved primarily in treat-
ing patients symptoms and preventing amputation,
have not been aware of the possible additional benefit
of risk factor reduction and secondary prevention.
Secondly, no medical speciality looks after PAD
patients systematically throughout the western
world, although the speciality angiology does exist
in a few countries. This is in contrast to CAD which
is attended by cardiologists who refer the surgical
cases to cardiac surgeons.
Under all circumstances, there remains a strong
need for increasing the awareness among phycisiansEur J Vasc Endovasc Surg Vol 24, July 2002seeing and treating PAD patients, that risk factor
reduction is important and that secondary medical
prophylaxis is necessary in PAD patients.
Who should take responsibility for risk factor
reduction in patients with PAD?
My opinion is that only one person is capable of
treating all aspects of peripheral arterial disease ±
namely the vascular surgeon. Since we are aware
of the pathogenesis and hemodynamic aspects of
atherosclerotic disease, the additional task of offering
risk factor reduction and secondary medical preven-
tion is only minor. Most patients are already seen
in our outpatient clinics ± the claudicant treated con-
servatively will be seen again after a few months to
evaluate the effect of walking exercise and the patient
operated with an in-situ bypass will be offered graft
surveillance.
Comprehensive risk factor identification and reduc-
tion in the vascular surgical outpatient clinic does
require extra resources. However, much of the work
may be done by someone other than the vascular
surgeon. For instance, smoking cessation therapy,
dietary instruction and supervised walking exercise
may be offered by vascular nurses. In Gentofte Uni-
versity Hospital, the vascular nurses provide the ser-
vices. In addition to the traditional tasks of measuring
ankle pressures and performing duplex scans, the
nurses offer smoking cessation therapy and dietary
instruction when the patient has been seen by the
vascular surgeon. Medical treatment with platelet
inhibitor's is considered for all patients and statins
are prescribed and monitored according to protocols.
Embracing all aspects of diagnosis, prevention and
treatment in one clinic not only improves the service
to the patient, it might also improve the results of
therapy. There is every reason to believe, that the
compliance of a claudicant to follow life style advice,
will be better if the patient is seen regularly in one
clinic. It is our experience that many patients referred
to other departments for smoking cessation advice
or dietary instruction never show up. Providing
counselling immediately when the patient is already
in the vascular clinic increases the likelihood of
patient compliance.
Can vascular surgeons take responsibility for this
extra task?
The major challenge is whether or not vascular sur-
geons wish to take on the responsibility of total care
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specialists in internal medicine interested in providing
the required secondary prevention. However, if vas-
cular surgeons turn over this task to specialists in
internal medicine, these `` colleagues'' will begin to
manage the claudicants walking problems as well,
since many will not require interventional treatment.
Moreover, patients may be referred for angiography
and possibly endovascular treatment without invol-
ving the vascular surgeon. If one follows that devel-
opment, the vascular surgeon would become the
same as cardiac surgeons i.e. a `` surgical technician''
for the cardiologists.
In my mind, the future vascular surgeon shall be
trained to understand and treat the diseases which
affect the patients we see. This will require some
additional training in internal medicine, but on the
other hand, we may not in the future need to
be trained so much in general surgery. Additionally,
the developments within endovascular treatment seen
over the last decade, requires us to be trained in this
aspect as well. Thus, the future vascular surgeon will
be a vascular specialist capable of treating the whole
patient with PAD.
Other organisations are of course possible and in
large centres, angiologists may be part of the vascular
surgical unit. Certainly, complicated medical cases
should be dealt with collaborating with specialists
within internal medicine, i.e. severe hypertension
and diabetes. However, it must result in improved
patient care if all persons involved in the treatment
of PAD patients have a similar background, focussed
on development and treatment of PAD. Educating all
physicians involved as vascular specialists they may
subspecialise afterwards, i.e. like today's situation in
many other specialities.
In Denmark, specialist training is currently being
redefined for all specialities. Within our field, the
Danish Vascular Surgical Society is currently defining
the `` specialist of vascular disease'' along the lines
mentioned above, including training in endovascular
techniques and medical treatment of the underlying
diseases in patients with PAD.
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COMMENTARY
Is There a Need for the Medical Angiologist?
J. OÈ stergren and B. Fagrell
Department of Medicine, Karolinska Hospital, Stockholm, Sweden
In an editorial in this issue of the journal Henrik
Sillesen gives a comprehensive and excellent sum-
mary of the current status of the medical management
of patients with peripheral vascular diseases. It is
acknowledged that coronary heart disease is crucial
regarding the prognosis and that optimal treatment of
risk factors is very important for the patient.1,2 We can
all agree with this, but there are diverging opinions on
how this shall be achieved. Sillesen is arguing that the
vascular surgeon should be the only physician (the
`` vascular specialist'') primarily involved in diagnos-
ing and treating the patient with peripheral vascular
diseases. He states that this would require further
training of the vascular surgeon in internal medicine
for a period of time.
Of course, we all agree that the vascular surgeon is
the colleague that should handle the scalpel in the
operating theatre. His special skills and training are
obviously a prerequisite for a successful immediate
outcome of a surgical vascular intervention. However,
for the patient it is at least of equal importance that
also the long-term outcome is successful, which is
dependent on several factors, i.e. concomitant diseases
and risk factors. In many instances the vascular sur-
geon has a thorough knowledge of medical treatments
and preventive measures, which makes him suitable
also for the more generalised treatment of this patient
group. However, this is not always the case ± and
should it preferably be like that?
Personally, we seriously doubt if this is the best way
of handling the often very complicated vascular
patient. In order to be able to provide optimal care
for this diverse patient group, one would need to be
fully trained in several fields of medicine; e.g. cardi-
ology, angiology, diabetology, and nephrology. As, no
individual can effectively deal with all these specific
problems, the solution is teamwork. As the cardiolo-
gist needs the thoracic surgeon for treatment of many
patients with coronary artery disease, the vascular
surgeon needs the internal specialist for optimal care
of the claudicant who often suffers from concomitant
angina pectoris, renal insufficiency, diabetes or chron-
ic obstructive lung disease.
In the editorial, the relationship between cardiolo-
gists and cardiac surgeons is condemned and a similar
relationship between angiologists and vascular sur-
geons adhered. We do not agree as a well-trained
and experienced angiologist is just the right person
in the team to take care of the vascular patient with
generalised atherosclerosis.3
Other vascular conditions that would benefit from
the experience of an angiologist are vasospastic dis-
orders, thrombophilias, and genetic disorders. The
inflammatory process is now increasingly recognised
as an important contributor to the atherosclerotic
process,4 and knowledge of this complex problem is
consequently of importance in the future.
At many centres there is an increasing cooperation
between vascular surgeons and angiologists even if
this speciality is only formally recognised in a few
countries. In some centres vascular surgeons and
angiologists belong to the same department, and this
may be the best model of care. Instead of protecting
our professional boundaries we should focus pri-
marily on the patient and his or her needs. We wel-
come the suggestion that vascular surgeons should be
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trained in non-surgical aspects of vascular disease, but
we doubt if they will have the interest and capacity
which is required to also fully deal with the complex
non-surgical parts of vascular medicine. We think
there will always be an important and specific role
for the medical angiologist. If we all work together
using the specific knowledge and skills, present in
different specialities, we will get as close as possible
to the optimal treatment of our patients.
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